Top stories

Bleak Winter! Why analysts are hinting at painful October even after 8 weeks of Nifty correction?

• US yields above 5%, a firm dollar, higher crude prices and rupee weakness weigh on India
• Higher crude and a weaker rupee pressure Indian importers and raise inflation risks for rate-sensitive sectors

IPO Calendar: Quiet week ahead after Rs 39,000 crore September rush, but Street to see 29 listings

• September saw a ₹39,000 crore IPO rush after a muted first four months of FY27
• The week ahead is quiet, but 29 listings are expected
• IPO activity and liquidity shape opportunities for Indian investors in new listings

Indian stocks face a cyclical correction, not a deeper earnings reset: Mahindra Manulife MF CIO

• The CIO characterises the market decline as a cyclical correction, not a deeper earnings reset
• Near-term uncertainties include energy price volatility, geopolitical tensions and AI-led impacts

Large caps face investor apathy, mid and small caps fuel euphoria

• Investor sentiment towards large-cap stocks is currently apathetic, despite improved valuations in the market
• Retail investors are increasingly enthusiastic about mid- and small-cap stocks
• Retail-led enthusiasm in mid- and small-caps raises volatility risk for Indian investors in these stocks

More than half of mid-to-large cap companies fail to deliver returns in 2026

• More than half of Indian mid-to-large companies with market caps above ₹1,000 crore have lost value in 2026
• Eight companies have experienced…

Slew of corrections dent largecap funds' long-term return picture

• Average five-year performance was hardly above fixed-income returns

Cheaper, fresh-issue IPOs deliver stronger gains for investors who hold on

• Low-P/E IPOs delivered stronger post-listing gains
• Expensive issues saw returns front-loaded at listing

New launches, chronic portfolio to maintain growth for Zydus Lifesciences

• Domestic formulations, chronic therapies and US launches have supported Zydus Lifesciences’ growth and rally
• Valuations now stand above…
• Growth supports Zydus Lifesciences, though elevated valuations may limit further gains

IPO boom: 69 Indian companies raise Rs 90,500 crore in Q3 despite stock market sell-off; what's next

Nifty slips below 22,500 as Sensex sheds 571 points; breakdown below 22,000 flagged

• Nifty 50 may break below 22,000, with no government commentary after successive market crashes
• Sensex shed 571 points as Nifty fell below 22,500
• The sell-off weighs on Indian equities, including large-cap and domestic-market stocks

Nifty 500 stocks fall up to 70% from 52-week highs; why broad market recovery may remain elusive in short term

• Nifty 500 stocks are down by as much as 70% from their 52-week highs
• Deep drawdowns and a weak recovery outlook weigh on Indian small- and mid-cap sentiment

5 stocks with consistent score improvement and upside potential of up to 33% in 1 year, according to analysts

• The market has been falling for close to a month-and-a-half, with occasional bounces
• The headline cites five stocks with up to 33% analyst upside in one year

‘Cash flow statement can't lie’ is the most expensive assumption in the stock market. That number can be dressed up too

Equities may average 15% over time, but very few years actually return 15%. What should investors expect?

I’m even more bullish about stocks than a year ago

• The writer says they are more bullish on stocks than a year ago, despite having sold everything by late October